AT-1413

AT-1413 (0.5-1.25 µg/mL) binds to CD43s on melanoma cell lines, some breast cancer cell lines, myeloid leukemia cell lines, as well as 86% of short-term cultured melanoma samples, as detected by flow cytometry^[1].
AT-1413 (10 µg/mL) binds to CD43s in 72% of melanoma tissue samples, but does not bind to adjacent healthy skin cells, as detected by immunohistochemistry^[1].
AT-1413 (3 h) recognizes the sialylated epitope of CD43 (CD43s) on the 136.2 and A375 melanoma cell lines^[1].
AT-1413 (1-25 µg/mL; 4 h) induces antibody-dependent cellular cytotoxicity against the A375, 136.2 and BLM melanoma cell lines, as well as the patient-derived melanoma samples MEL12.07, MEL06.07 and MEL99.08, in vitro^[1].
AT1413 (0.001-20 μg/mL) potently induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in SH2-type AML cells in vitro, with EC₅₀ values of 1.1 nM and 12.4 nM, respectively, but does not induce cytotoxicity in non-malignant HAEC, HUVEC or healthy granulocytes^[2].
AT1413 (3 h) specifically binds to the unique sialylated epitope (CD43s) located between amino acid residues 133 and 165 of the CD43 protein, which is expressed in human THP-1 and Molm13 acute myeloid leukemia (AML) cell lines as well as the mouse WEHI-3b AML cell line^[2].
AT1413 specifically binds to CD43s on the surface of AML/MDS blasts, human AML cell lines, and mouse WEHI-3b AML cells, while it shows weak binding to some non-malignant myeloid cells and endothelial cells, and no binding to healthy lymphoid cells or non-hematopoietic cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.